INTRODUCTION {#s1}
============

Breast cancer (BC) is the most common type of cancer and the leading cause of cancer deaths among women worldwide (particularly in less developed regions including East Asian countries, which accounted for 324,000 deaths or 14.3% of the total) \[[@R1]\]. According to GLOBOCAN 2012, 187,213 individuals were diagnosed with BC in China in 2012, and 47,984 of these individuals died of the disease \[[@R2]\]. BC is a multifactorial disease that has been associated with various factors including age, gender, ethnicity, family history, personal history, lifestyle, as well as both hormonal and non-hormonal risk factors \[[@R3]\]. Hereditary BC clusters in families and is typically diagnosed at an earlier age \[[@R4]\]. Studies of twins have indicated that the risk of BC is higher for a monozygotic twin of a co-twin, suggesting that genetic factors play an important role in BC development \[[@R5]\]. Single nucleotide polymorphisms (SNPs) also play an important role in the genetic susceptibility to BC. Many genes have been associated with a moderate or high lifetime risk of BC including *BRCA1*, *BRCA2*, *PALB2, ATM*, and *CHEK2*. In addition, common variants at more than 70 loci have been identified through GWAS and large-scale replication studies \[[@R6]--[@R9]\].

The testis-specific Y-encoded-like protein 6 (*TSPYL6*) gene, located on human chromosome 2p16.2, is a member of the *TSPY/TSPYL/SET/NAP-1* (TTSN) superfamily that includes *TSPYL1, TSPYL2, TSPYL3, TSPYL4,* and *TSPYL5* \[[@R10]\]. Upregulation of *TSPYL6* has been observed in both benign and malignant cells. The *TSPYL6* protein has been associated with chromatin and nucleosome assembly \[[@R11]\]. However, the specific functions of *TSPYL6* are not yet clear. Norling et al. \[[@R12]\] sequenced the *TSPYL6* gene in an entire Sweden patient cohort, but no inactivating mutations were identified. Additionally, no studies have investigated correlations between the *TSPYL6* gene and BC susceptibility. In this case-control study, we genotyped six SNPs in *TSPYL6*: rs843645, rs11125529, rs12615793, rs843711, rs11896604, and rs843706 and performed a comprehensive association analysis to identify SNPs associated with BC risk in Han Chinese women.

RESULTS {#s2}
=======

Participant characteristics {#s2_1}
---------------------------

A total of 183 patients with BC and 195 healthy individuals were enrolled in the study. The participant characteristics are shown in Table [1](#T1){ref-type="table"}. No significant differences in age, body mass index (BMI), or the menopause age were observed between patients in the case and control groups (*p* \> 0.05). The mean age of the participants was 45.35 years in the control group and 46.40 years in the case group. The mean BMI was 22.53 in the control group and 23.08 in the case group.

###### Basic characteristics of the control individuals and patients with breast cancer

  Characteristic                              Cases (*N* = 183)          Controls (*N* = 195)       *P* -value
  -------------------------- ---------------- -------------------------- -------------------------- -------------------------------------------
   Mean age ± SD                              46.40 ± 9.383 (*N*= 183)   45.35 ± 6.899 (*N*= 195)   0.218[^a^](#tfn_001){ref-type="table-fn"}
   Mean BMI ± SD                              23.08 ± 3.00 (*N*= 183)    22.53 ± 2.55 (*N* = 195)   0.056[^a^](#tfn_001){ref-type="table-fn"}
  Menopause                  Premenopausal    115 (62.8%)                119 (61.0%)                0.716[^b^](#tfn_002){ref-type="table-fn"}
                             Postmenopausal   68 (37.2%)                 76 (39.0%)                 
  Age of Menarche            ≤ 12             25 (13.7%)                                            
                             \> 12            158 (86.3%)                                           
  Breastfeeding Duration     ≤ 6              12 (6.5%)                                             
                             \> 6             158 (93.5%)                                           
  Clinical Stages            I/II             135 (73.8%)                                           
                             III/IV           48 (26.2%)                                            
  Estrogen Receptor          negative         60 (32.8%)                                            
                             positive         123 (67.2%)                                           
  Family Tumor History       no               156 (85.2%)                                           
                             yes              27 (14.8%)                                            
  Incipientw or Recurrence   Incipient        109 (59.9%)                                           
                             Recurrence       73 (40.1%)                                            
  Lymph node metastasis      no               105 (58.3%)                                           
                             yes              75 (41.7%)                                            
  Menopause                  no               115 (62.8%)                                           
                             yes              68 (37.2%)                                            
  Primiparous Age            \< 30            170 (96.6%)                                           
                             ≥ 30             6 (3.4%)                                              
  Procreative Times          \< 1             142 (81.1%)                                           
                             ≥ 1              33 (18.9%)                                            
  Progestrone Receptor       negative         75 (41.0%)                                            
                             positive         108 (59.0%)                                           
  Tumor Location             left             84 (45.9%)                                            
                             right            97 (53.0%)                                            
                             both             2 (1.1%)                                              
  Tumor Size (cm)            ≤ 3              94 (51.4%)                                            
                             \> 3             89 (48.6%)                                            
  Tumor Type                 carcinoma        165 (90.2%)                                           
                             others           18 (9.8%)                                             
  Whether fertility          no               7 (3.8%)                                              
                             yes              176 (96.2%)                                           

SD: Standard deviation. BMI: Body mass index (weight \[kg\]/height\[m\]^2^).

*P* value was calculated by Welch\'s *t* test.

*P* value was calculated by Pearson\'s χ^2^ test.

Association between *TSPYL6* polymorphisms and BC risk {#s2_2}
------------------------------------------------------

Detailed SNP data and the associations between various SNPs and BC risk are shown in Table [2](#T2){ref-type="table"}. Our data indicated that all 6 SNPs investigated were in Hardy-Weinberg equilibrium in the control subjects (*p* \> 0.05). No associations were observed between the alleles and BC risk in an allele model. We also performed a Bonferroni correction and determined that none of the SNPs showed statistical significant associations with BC risk.

###### Basic information of candidate SNPs in this study

  SNPs         Position   Band     Alleles[^A^](#tfn_003){ref-type="table-fn"}/[^B^](#tfn_004){ref-type="table-fn"}   MAF-control   MAF-case   HWE-p     OR      95% CI         *p*-x^2^
  ------------ ---------- -------- ---------------------------------------------------------------------------------- ------------- ---------- --------- ------- -------------- ----------
  rs843645     54474664   2p16.2   G/T                                                                                0.297         0.279      0.4968    0.913   0.666--1.251   0.57
  rs11125529   54475866   2p16.2   A/C                                                                                0.195         0.150      0.1695    0.731   0.499--1.069   0.105
  rs12615793   54475914   2p16.2   A/G                                                                                0.201         0.161      0.1166    0.764   0.525--1.109   0.156
  rs843711     54479117   2p16.2   C/T                                                                                0.487         0.544      0.1531    1.254   0.942--1.669   0.12
  rs11896604   54479199   2p16.2   G/C                                                                                0.221         0.167      0.0929    0.707   0.491--1.018   0.062
  rs843706     54480369   2p16.2   C/A                                                                                0.482         0.544      0.06103   1.281   0.962--1.705   0.090

SNPs: Single nucleotide polymorphisms; MAF: Minor allele frequency; HWE: Hardy-Weinberg equilibrium; OR: Odds ratio; CI: Confidence interval.

Minor alleles.

Major alleles.

We further assessed the association between each SNP and BC risk in an unconditional logistic regression analysis, which was performed using four models: additive, dominant, recessive, and genotype model (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). Rs11896604 was associated with a decreased risk of BC in a dominant model (odds ratio \[OR\] = 0.623, 95% confidence interval \[95% CI\] = 0.405--0.958, *p* = 0.031). Rs843706 was associated with an increased risk of BC under the recessive model (OR = 1.709, 95% CI = 1.055--2.770, *p* = 0.030) (Table [3](#T3){ref-type="table"}). Rs11125529 was associated with a decreased risk of BC under the genotype model (OR = 0.612, 95% CI = 0.391--0.959, *p* = 0.032) (Table [4](#T4){ref-type="table"}). Rs11896604 was associated with a decreased risk of BC in a genotype model (OR = 0.574, 95% CI = 0.370--0.891, *p* = 0.013). No statistical associations were detected under the other models. In addition, no positive results were observed after Bonferroni correction.

###### Single loci association with breast cancer risk (adjusted by age, BMI and menopause)

  SNP          Model             Genotype   Cases   Controls   OR (95% CI)            *P*
  ------------ ----------------- ---------- ------- ---------- ---------------------- -----------
  rs843645     Dominant model    T/T        99      94         1                      0.246
                                 G/G-G/T    84      101        0.785 (0.521--1.182)   
               Recessive model   T/T-T/G    165     180        1                      0.535
                                 G/G        18      15         1.259 (0.608--2.606)   
               Additive model    \-         \-      \-         0.904 (0.658--1.241)   0.532
  rs11125529   Dominant model    C/C        133     123        1                      0.057
                                 A/A-A/C    50      72         0.652 (0.419--1.013)   
               Recessive model   C/C-C/A    178     191        1                      0.618
                                 A/A        5       4          1.413 (0.364--5.488)   
               Additive model    \-         \-      \-         0.730 (0.491--1.085)   0.120
  rs12615793   Dominant model    G/G        129     120        1                      0.085
                                 A/A-A/G    54      74         0.682 (0.441--1.054)   
               Recessive model   G/G-G/A    178     190        1                      0.625
                                 A/A        5       4          1.402 (0.361--5.445)   
               Additive model    \-         \-      \-         0.755 (0.510--1.117)   0.159
  rs843711     Dominant model    T/T        39      46         1                      0.532
                                 C/C-C/T    144     149        1.169 (0.405--0.958)   
               Recessive model   T/T-T/C    128     154        1                      0.066
                                 C/C        55      41         1.563 (0.972--2.515)   
               Additive model    \-         \-      \-         1.261 (0.937--1.700)   0.126
  rs11896604   Dominant model    C/C        128     114        1                      **0.031**
                                 G/G-G/C    55      81         0.623 (0.405--0.958)   
               Recessive model   C/C-C/G    177     190        1                      0.644
                                 G/G        6       5          1.336 (0.391--4.564)   
               Additive model    \-         \-      \-         0.709 (0.484--1.039)   0.078
  rs843706     Dominant model    A/A        39      45         1                      0.603
                                 C/C-C/A    144     149        1.140 (0.696--1.866)   
               Recessive model   A/A-A/C    128     156        1                      **0.030**
                                 C/C        55      38         1.709 (1.055--2.770)   
               Additive model    \-         \-      \-         1.294 (0.958--1.750)   0.093

SNPs: Single nucleotide polymorphisms; OR: Odds ratio. CI: Confidence interval.

*P* value was calculated by Wald test. \**p* \< 0.05 indicates statistical significant.

###### The association between the single-nucleotide polymorphisms and BC risk in Genotype model (adjusted by age, BMI and menopause)

  Genotype     Cases   Controls   OR (95% CI)            *P*
  ------------ ------- ---------- ---------------------- -----------
  rs843645                                               
   TT          99      94         1.00 \[Ref\]           
   GT          66      86         0.729 (0.475--1.117)   0.147
   GG          18      15         1.139 (0.543--2.391)   0.730
  rs11125529                                             
   CC          133     123        1.00 \[Ref\]           
   AC          45      68         0.612 (0.391--0.959)   **0.032**
   AA          5       4          1.156 (0.304--4.404)   0.832
  rs12615793                                             
   GG          129     120        1.00 \[Ref\]           
   AG          49      70         0.651 (0.419--1.013)   0.057
   AA          5       4          1.163 (0.305--4.432)   0.825
  rs843711                                               
   TT          39      46         1.00 \[Ref\]           
   CT          89      108        0.972 (0.583--1.620)   0.913
   CC          55      41         1.582 (0.879--2.848)   0.126
  rs11896604                                             
   CC          128     114        1.00 \[Ref\]           
   GC          49      76         0.574 (0.37--0.891)    0.013
   GG          6       5          1.069 (0.318--3.596)   0.915
  rs843706                                               
   AA          39      45         1.00 \[Ref\]           
   CA          89      111        0.925 (0.555--1.543)   0.766
   CC          55      38         1.670 (0.921--3.030)   0.092

OR: odd ratio; CI: confidence interval;

*p* value was calculated by Wald test. \**p* \< 0.05 indicates statistical significance.

In order to assess the associations between SNP haplotypes and BC risk, a Wald test was performed using an unconditional multivariate regression analysis. However, no positive results were observed (Table [5](#T5){ref-type="table"}, Figure [1](#F1){ref-type="fig"}).

###### Haplotype frequency and their association with BC risk in case and control subjects (adjusted by age, BMI and menopause)

  -----------------------------------------------------------------------------------------------------------------
  SNPs                                        Haplotype   Freq %   *P1*    OR      95% CI   *P2*            
  ------------------------------------------- ----------- -------- ------- ------- -------- ------- ------- -------
  rs843645\|rs11125529\|rs12615793\|rs8437\   TAATGA      0.150    0.192   0.126   0.745    0.501   1.108   0.146
  11\|rs11896604\|rs843706                                                                                  

                                              TCGTGA      0.016    0.023   0.510   0.741    0.256   2.149   0.581

                                              GCGTCA      0.276    0.292   0.619   0.912    0.662   1.257   0.574

                                              TCGCCC      0.530    0.474   0.126   1.266    0.939   1.707   0.122
  -----------------------------------------------------------------------------------------------------------------

*\*P*-value \< 0.05 indicates statistical significance.

*P1*- values were calculated from two-sided Chi-squared test.

*P2* -values were calculated by unconditional logistic regression.

The reference standard for each haplotype is the other haplotype.

![Haplotype block map for all the SNPs of the *TSPYL6* gene](oncotarget-07-54771-g001){#F1}

Association between *TSPYL6* polymorphisms and BC patient clinicopathological features {#s2_3}
--------------------------------------------------------------------------------------

We next analyzed the association between *TSPYL6* polymorphisms and BC patient clinicopathological features, which included age, age of menarche, BMI, breastfeeding duration, clinical stage, estrogen receptor status, family history of cancer, procreative time, progesterone receptor status, tumor location, tumor size (cm), tumor type, incipient recurrence, presence of lymph node metastasis, age of menopause, and prim parous age. Positive results are shown in (Table [6A](#T6a){ref-type="table"}, [6B](#T6b){ref-type="table"}). For rs11125529, we found that more recurrent BC patients had the AA + CA genotype than the CC genotype (OR = 2.321, 95% CI = 1.192--4.521, *p* = 0.012) (Table [6A](#T6a){ref-type="table"}). For rs843711, the CT + CC genotype was observed less frequently in patients with clinical stage III/IV disease (OR = 0.411, 95% CI = 0.194--0.869, *p* = 0.018) and in patients with recurrent BC (OR = 0.458, 95% CI = 0.222--0.944, *p* = 0.032) than the TT genotype (Table [6A](#T6a){ref-type="table"}). Our results suggested that the frequency of recurrent BC patients with the CC genotype of rs11896604 was higher than the frequency of patients with the GG + CG genotype (OR = 2.471, 95% CI = 1.290--4.734, *p* = 0.006) (Table [6B](#T6b){ref-type="table"}). Finally, the CA + CC genotype of rs843706 was more frequently observed in patients with clinical stage III/IV disease (OR = 0.411, 95% CI = 0.194--0.869, *p* = 0.018) and in patients with recurrent BC (OR = 0.458, 95% CI = 0.222--0.944, *p* = 0.032) than the AA genotype (Table [6B](#T6b){ref-type="table"}). No statistical associations were detected between the other loci and the clinical parameters that were investigated.

###### The Associations between *TSPYL6* polymorphisms and clinical characteristics of breast cancer patients

  Variables                        rs11125529   rs843711                                                                                                               
  -------------------------------- ------------ ---------- ------- ---------------- ---------------------------------------------- ----- ---- ------- ---------------- ----------------------------------------------
  Age                              50           133                                                                                144   39                            
   ≤ 40                            14           43         1       (reference)                                                     41    16   1       (reference)      
   \> 40                           36           90         1.229   (0.600--2.515)   0.573                                          103   23   1.748   (0.839--3.639)   0.133
  Age of Menarche                  50           133                                                                                144   39                            
   ≤ 12                            5            20         1       (reference)                                                     22    3    1       (reference)      
   \> 12                           45           113        0.628   (0.222--1.775)   0.377                                          122   36   2.164   (0.612--7.646)   0.221
  BMI                              50           133                                                                                144   39                            
   ≤ 24                            34           87         1       (reference)                                                     98    23   1       (reference)      
   \> 24                           16           46         0.89    (0.445--1.780)   0.742                                          46    16   0.675   (0.326--1.397)   0.288
  Breastfeeding Duration           46           124                                                                                133   37                            
   ≤ 6                             3            9          1       (reference)                                                     10    2    1       (reference)      
   \> 6                            43           115        0.891   (0.230--3.448)   0.868                                          123   35   1.423   (0.298--6.797)   0.657
  Clinical Stages                  50           133                                                                                144   39                            
   I/II                            38           97         1       (reference)                                                     112   23   1       (reference)      
   III/IV                          12           36         0.851   (0.401--1.807)   0.674                                          32    16   0.411   (0.194--0.869)   **0.018**[\*](#tfn_007){ref-type="table-fn"}
  Estrogen Receptor                50           133                                                                                144   39                            
   negative                        17           43         1       (reference)                                                     49    11   1       (reference)      
   positive                        33           90         0.927   (0.466--1.847)   0.83                                           95    28   0.762   (0.350--1.658)   0.492
  Family Tumor History             50           133                                                                                144   39                            
   no                              8            114        1       (reference)                                                     121   35   1       (reference)      
   yes                             42           19         1.143   (0.465--2.807)   0.771                                          23    4    1.663   (0.539--5.031)   0.372
  Procreative Times                47           128                                                                                138   37                            
   \< 1                            37           105        1       (reference)                                                     112   30   1       (reference)      
   ≥ 1                             10           23         0.81    (0.353--1.862)   0.62                                           26    7    1.005   (0.398--2.539)   0.991
  Progestrone Receptor             50           133                                                                                144   39                            
   negative                        22           53         1       (reference)                                                     59    16   1       (reference)      
   positive                        28           80         0.843   (0.437--1.627)   0.611                                          85    23   1.002   (0.488--2.058)   0.995
  Tumor Location                   50           133                                                                                144   39                            
   left                            22           62         1       (reference)                                                     66    18   1       (reference)      
   right                           28           69         1       (reference)                                                     77    20   1       (reference)      
   both                            0            2          \-\--   \-\--            0.631                                          1     1    \-\--   \-\--            0.603
  Tumor Size (cm)                  50           133                                                                                144   39                            
   ≤ 3                             24           70         1       (reference)                                                     76    18   1       (reference)      
   \> 3                            26           63         1.204   (0.628--2.308)   0.576                                          68    21   0.767   (0.377--1.559)   0.463
  Tumor Type                       50           133                                                                                144   39                            
   Infiltrating ductal carcinoma   47           118        1       (reference)                                                     128   37   1       (reference)      
   others                          3            15         1.992   (0.551--7.198)   0.285                                          16    2    0.432   (0.095--1.967)   0.266
  Incipience/Recurrence            49           133                                                                                144   38                            
   Incipience                      22           87         1       (reference)                                                     92    17   1       (reference)      
   Recurrence                      27           46         2.321   (1.192--4.521)   **0.012**[\*](#tfn_007){ref-type="table-fn"}   52    21   0.458   (0.222--0.944)   **0.032**[\*](#tfn_007){ref-type="table-fn"}
  Lymph node metastasis            49           131                                                                                141   39                            
   no                              29           76         1       (reference)                                                     83    17   1       (reference)      
   yes                             20           55         0.953   (0.489--1.857)   0.887                                          58    22   0.904   (0.442--1.851)   0.783
  Menopause                        50           133                                                                                144   39                            
   no                              27           88         1       (reference)                                                     87    28   1       (reference)      
   yes                             23           45         1.666   (0.859--3.230)   0.129                                          57    11   1.668   (0.770--3.614)   0.192
  Primiparous Age                  47           129                                                                                139   37                            
   \< 30                           45           125        1       (reference)                                                     136   34   1       (reference)      
   ≥ 30                            2            4          0.72    (0.127--4.006)   0.709                                          3     3    4       (0.773--20.70)   0.076

###### The Associations between *TSPYL6* polymorphisms and clinical characteristics of breast cancer patients

  Variables                        rs11896604   rs843706                                                                                                               
  -------------------------------- ------------ ---------- ------- ---------------- ---------------------------------------------- ----- ---- ------- ---------------- ----------------------------------------------
  Age                              55           128                                                                                144   39                            
   ≤ 40                            16           41         1       (reference)                                                     41    16   1       (reference)      
   \> 40                           39           87         1.149   (0.576--2.291)   0.694                                          103   23   1.748   (0.839--3.639)   0.133
  Age of Menarche                  55           128                                                                                144   39                            
   ≤ 12                            6            19         1       (reference)                                                     22    3    1       (reference)      
   \> 12                           49           109        0.702   (0.264--1.868)   0.477                                          122   36   2.164   (0.612--7.646)   0.221
  BMI                              55           128                                                                                144   39                            
   ≤ 24                            38           83         1       (reference)                                                     98    23   1       (reference)      
   \> 24                           17           45         0.825   (0.419--1.624)   0.578                                          46    16   0.675   90.326--1.397    0.288
  Breastfeeding Duration           51           119                                                                                133   37                            
   ≤ 6                             3            9          1       (reference)                                                     10    2    1       (reference)      
   \> 6                            48           110        0.764   (0.198--2.946)   0.695                                          123   35   1.423   (0.298--6.797)   0.657
  Clinical Stages                  55           128                                                                                144   39                            
   I/II                            43           92         1       (reference)                                                     112   23   1       (reference)      
   III/IV                          12           36         0.713   (0.338--1.505)   0.374                                          32    16   0.411   (0.194--0.869)   0.018\*[\*](#tfn_007){ref-type="table-fn"}
  Estrogen Receptor                55           128                                                                                144   39                            
   negative                        19           41         1       (reference)                                                     49    11   1       (reference)      
   positive                        36           87         0.893   (0.458--1.742)   0.74                                           95    28   0.762   (0.350--1.658)   0.492
  Family Tumor History             55           128                                                                                144   39                            
   no                              45           111        1       (reference)                                                     121   35   1       (reference)      
   yes                             10           17         1.151   (0.617--3.410)   0.391                                          23    4    1.663   (0.539--5.131)   0.372
  Procreative Times                52           123                                                                                138   37                            
   \< 1                            41           101        1       (reference)                                                     112   30   1       (reference)      
   ≥ 1                             11           22         0.812   (0.361--1.824)   0.614                                          26    7    1.005   (0.398--2.539)   0.991
  Progestrone Receptor             55           128                                                                                144   39                            
   negative                        25           50         1       (reference)                                                     59    16   1       (reference)      
   positive                        30           78         0.769   (0.406--1.457)   0.42                                           85    23   1.002   (0.488--2.058)   0.995
  Tumor Location                   55           128                                                                                144   39                            
   left                            25           59         1       (reference)                                                     66    18   1       (reference)      
   right                           30           67         1       (reference)                                                     77    20   1       (reference)      
   both                            0            2          \-\--   \-\--            0.638                                          1     1    \-\--   \-\--            0.603
  Tumor Size (cm)                  55           128                                                                                144   39                            
   ≤ 3                             27           67         1       (reference)                                                     76    18   1       (reference)      
   \> 3                            28           61         1.139   (0.605--2.144)   0.686                                          68    21   0.767   (0.377--1.559)   0.463
  Tumor Type                       55           128                                                                                144   39                            
   Infiltrating ductal carcinoma   52           113        1       (reference)                                                     128   37                            
   others                          3            15         2.301   (0.638--8.295)   0.192                                          16    2    0.432   (0.095--1.967)   0.266
  Incipience/Recurrence            54           128                                                                                144   38                            
   Incipience                      24           85         1       (reference)                                                     92    17   1       (reference)      
   Recurrence                      30           43         2.471   (1.290--4.734)   **0.006**[\*](#tfn_007){ref-type="table-fn"}   52    21   0.458   (0.222--0.944)   **0.032**[\*](#tfn_007){ref-type="table-fn"}
  Lymph node metastasis            54           126                                                                                141   39                            
   no                              33           72         1       (reference)                                                     83    22   1       (reference)      
   yes                             21           54         0.848   (0.442--1.627)   0.621                                          58    17   0.904   (0.442--1.851)   0.783
  Menopause                        55           128                                                                                144   39                            
   no                              32           83         1       (reference)                                                     87    28   1       (reference)      
   yes                             23           45         1.326   (0.694--2.532)   0.393                                          57    11   1.668   (0.770--3.614)   0.192
  Primiparous Age                  52           124                                                                                139   37                            
   \< 30                           50           120        1       (reference)                                                     136   34   1       (reference)      
   ≥ 30                            2            4          0.833   (0.148--4.697)   0.836                                          3     3    4       (0.773--20.70)   0.076

BMI: body mass index; CI: confidence interval. OR: odds ratio.

Adjusted for Age, Age of Menarche, BMI, Breastfeeding Duration, Clinical Stages, Estrogen Receptor, Family Tumor History, Procreative Times, Progestrone Receptor, Tumor Location, Tumor Size (cm), Tumor Type, Incipient/Recurrence, Lymph node metastasis, Menopause and Primiparous Age.

Two-sided Chi-square test for the distributions of genotype frequencies.

*p* \< 0.05 indicates statistical significance.

DISCUSSION {#s3}
==========

In this study, we investigated the association between SNPs in the TSPYL6 gene and BC risk in Han Chinese women. We found that four SNPs (rs11896604, rs843706, rs11125529, and rs843711) were associated with the risk of BC in this population. Rs11896604 was associated with a decreased risk of BC in a dominant and genotype model, but the various genotypes were associated with an increased risk of recurrence in BC patients. An association between this locus and other diseases has not been previously reported. Rs843706 was associated with an increased risk of BC in a recessive model, but there was a decreased association between the SNP and the risk of recurrence as well as with clinical stage III/IV BC.

We are the first to demonstrate an association between this locus and BC susceptibility. Rs11125529 was associated with a decreased risk of BC in a genotype model, but an increased risk of recurrence. Although Ding et al. reported neither the genotype nor the allele frequencies at rs11125529 in *ACYP2* differed significantly between coronary heart disease patients and normal controls \[[@R13]\]. The association between the telomere length-related variant rs11125529 in *ACYP2* and gastric cancer risk was previously investigated in a Chinese population, but no significant association was identified \[[@R14]\]. We found that the rs843711 genotypes in the *TSPYL6* gene were inversely correlated with clinical stage III/IV BC. Finally, rs843645 and rs12615793 were not associated with the risk of BC.

The function of *TSPYL6* may be similar to those of other members of the TTSN superfamily. However, the molecular mechanisms underlying *TSPYL6* function have not been elucidated. Mutation of *TSPYL* can cause sudden infant death with dysgenesis of the testes (SIDDT) in affected males, indicating that *TSPYL* is important for the development of the testis and other tissues such as the brain \[[@R15]\]. Although *TSPYL* is expressed in all tissues \[[@R16]\], the role of *TSPYL* in tumor cells is not clear. The *TSPYL4* gene is located 25 kb from *TSPYL*, however no coding variants were identified in affected individuals with direct sequencing. The *TSPYL1* gene does not contain any introns, but the exact composition has not been determined \[[@R17]\].

*TSPYL2* gene and cyclin B can inhibit cell proliferation by arresting cell growth in response to DNA damage \[[@R18]\]. Thus, it has been suggested that *TSPYL2* is a negative regulator of cell cycle progression. The *TSPYL2* gene is silenced in glioma and malignant lung tissue, and in certain lung cancer cell lines \[[@R19]\]. Overexpression of *TSPYL2* can inhibit human lung and breast cancer cell lines \[[@R20]\]. However, there is limited evidence for a direct function of *TSPYL2* in cell cycle control. Interestingly, the *TSPYL5* gene has been reported to suppress gastric cancer development \[[@R21]\]. Further studies are required to characterize the function of *TSPYL6* and elucidate the mechanisms underlying the association between the *TSPYL6* and BC susceptibility. Currently, the relationship between clinical characteristics in BC patients and *TSPYL6* gene expression/function is not clear.

Our study is the first to demonstrate that polymorphisms in *TSPYL6* affect the pathogenesis of BC and are associated with clinicopathological characteristics of BC patients. Collectively, the results provide insight into the pathogenesis of BC. Although this study had sufficient statistical power, there were still some intrinsic limitations. First, the sample size was relatively small (183 cases and 195 controls). Therefore, our findings must be confirmed in studies with larger sample sizes as well as in a meta-analysis. Additionally, we only analyzed Han Chinese women. Therefore, our results must be validated in studies of other populations. Finally, although we identified significant associations between four SNPs (rs11896604, rs843706, rs11125529, and rs843711) and BC susceptibility, the mechanisms responsible for the associations are still unclear. Further studies of *TSPYL6* and other members of the TTSN superfamily are necessary to dissect the mechanisms by which polymorphisms in these genes contribute to BC risk. Hereditary, endocrine, environmental, and life style factors should be also considered.

We performed Bonferroni correction in our statistical analysis, but found no statistical significant associations between *TSPYL6* SNPs and risk of BC. This may be due to the relatively small sample size, the selection criteria for *TSPYL6* SNPs (minor allele frequency \[MAF\] \> 5%), and the weakness of Bonferroni correction itself (the interpretation of a finding depends on the number of other tests performed). True differences may have been deemed non-significant given the likelihood of type II errors.

MATERIALS AND METHODS {#s4}
=====================

Study participants {#s4_1}
------------------

A total of 183 patients with BC and 195 healthy women were included in this study. The patients were treated at the Second Affiliated Hospital of Xi\'an Jiao Tong University between January 2013 and November 2015. All demographic and related clinical data including residential region, age, ethnicity, and education status were collected through a face-to-face questionnaire and a review of medical records. The clinical and demographic characteristics of the patients are shown in Table [1](#T1){ref-type="table"}. Patients who had been recently diagnosed with primary BC (confirmed by histopathological analysis) were included in the study. Patients diagnosed with other types of cancers or who underwent radiotherapy or chemotherapy were excluded. Control patients who had undergone annual health evaluations were recruited from health checkup centers affiliated with our institution. All controls were matched with cases based on age (*p* = 0.218) and ethnicity. All control patients had no history of cancer. Factors that could influence the mutation rate were minimized. The participants were women who were ≥ 18 years old with good mental health and no blood relatives with BC going back three generations. This study was performed in accordance with the Chinese Department of Health and Human Services regulations for the protection of human research subjects. Informed consent was obtained from all participants and the study protocols were approved by the Institutional Review Board of Xi\'an Jiao Tong University.

SNP selection and genotyping {#s4_2}
----------------------------

Validated SNPs that had a MAF \> 5% in the HapMap Asian population were selected for the association analysis \[[@R12], [@R20], [@R22], [@R23]\]. Venous blood samples (5 mL) were collected from each patient during a laboratory examination. DNA was extracted from whole blood samples using the Gold Mag-Mini Whole Blood Genomic DNA Purification Kit (version 3.0; TaKaRa, Japan) \[[@R24]\]. The DNA concentration was measured by spectrometry (DU530 UV/VIS spectrophotometer, Beckman Instruments, Fullerton, CA, USA). The Sequenom MassARRAY Assay Design 3.0 software (Sequenom, Inc, San Diego, CA, USA) was used to design the multiplexed SNP Mass EXTEND assay. Genotyping was performed using a Sequenom MassARRAY RS1000 (Sequenom, Inc.) according to the manufacturer\'s protocol \[[@R25]\]. The SequenomTyper 4.0 Software™ (Sequenom, Inc.) was used to manage and analyze the data \[[@R26]\]. The primers corresponding to each SNP are shown in Table [7](#T7){ref-type="table"}. Based on these results, the following six SNPs were selected: rs843645, rs11125529, rs12615793, rs843711, rs11896604, and rs843706. The SNP data are shown in Table [3](#T3){ref-type="table"}.

###### Primers used for this study

  SNP_ID       1st-PCRP                           2nd-PCRP                          UEP_SEQ
  ------------ ---------------------------------- --------------------------------- ------------------------------
  rs843645     ACGTTGGATGGAAATCTGA ATACCACCTAC    ACGTTGGATGACAGTGCCTTTA GCAAGGTG   TCATAGGCACTACT GTATC
  rs11125529   ACGTTGGATGGAGCTTAGTT GTTTACAGATG   ACGTTGGATGCCGAAGAAAAG AAGATGAC    AGAAAAGAAGATG ACTAAAACAT
  rs12615793   ACGTTGGATGTTTGAGCTTAG TTGTTTAC     ACGTTGGATGATCTTGGCCCTT GAAGAA     AAATTGAGTGACAA\| ATATAAACTAC
  rs843711     ACGTTGGATGGACAAAGGACC TTACAACTC    ACGTTGGATGTGCCTTGTGGGA ATTAGAGC   gggaTCAGGGAACCA GTGCAAA
  rs11896604   ACGTTGGATGAAGTCAGAATA GTGCTTAC     ACGTTGGATGTGTCTCTGACCT AGCATGTA   GTTAAGCTTGCAA GGAG
  rs843706     ACGTTGGATGTGAAAGCCAT AAATATTTTG    ACGTTGGATGTGAATAACTTGG TCTTATC    cACTTGGTCTTATCT GATGC

Statistical analysis {#s4_3}
--------------------

Chi-squared tests (categorical variables) and Student\'s *t-*tests (continuous variables) were used to evaluate the differences in the demographic characteristics between the cases and controls \[[@R27]\]. The Hardy-Weinberg equilibrium of each SNP was assessed in order to compare the expected frequencies of the genotypes in the control patients. All of the minor alleles were regarded as risk alleles for BC susceptibility. To evaluate associations between the SNPs and risk of BC in the four models (genotype, dominant, recessive, and additive), ORs and 95% CIs were calculated using unconditional logistic regression analysis \[[@R28]\]. In multivariate analyses, unconditional logistic regression was used to assess the association between each SNP and the risk of BC after adjusting for BMI, age, and menopause \[[@R28]\]. Linkage disequilibrium analysis and SNP haplotypes were analyzed using the Haploview software package (version 4.2) and the SHEsi software platform (<http://www.nhgg.org/analysis/>) \[[@R29]\]. All statistical analyses were performed using the SPSS version 17.0 statistical package (SPSS, Chicago, IL, USA) and Microsoft Excel. A *p* \< 0.05 was considered statistically significant and all statistical tests were two-sided.

CONCLUSIONS {#s5}
===========

In summary, we have identified four novel associations between SNPs (rs11896604, rs843706, rs11125529, and rs843711) in *TSPYL6* and BC. Our results suggest that these SNPs may contribute to BC development and possibly other complex genetic traits. These SNPs may function as molecular markers of BC susceptibility, and could therefore be used as diagnostic and prognostic markers in clinical studies of BC patients.
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